Navigation Links
Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications
Date:5/11/2012

overall than the broader population," said Dr. Woody Eisenberg, chief medical officer for Medicare and a co-author of the research.  "Still, the issue of nonadherence is significant and is one that can be addressed by health care policy makers that are trying to manage Medicare costs by including pharmacists as providers of clinical care with a focus on adherence to essential medications."  

Express Scripts has recently launched ScreenRx(SM), a breakthrough solution in the fight against the nation's costliest health condition: medication nonadherence.

ScreenRx is a proprietary adherence solution from the Express Scripts Research & News Solutions Lab. It detects future risk for nonadherence and tailors interventions for individual patients. Leveraging the power of predictive modeling, the tool identifies patients at highest risk for not following their doctors' orders. Once identified, patients receive personalized interventions to help them stay on their therapy.

In 2011, medication nonadherence cost the United States healthcare system $317.4 billion in treating medical complications that could have been avoided if patients had taken their medication.  This amount is higher than the total medical cost of treating diabetes, congestive heart failure and cancer combined.

Details of Studies

Combined, both studies examined the pharmacy and medical claims of more than 500,000 Americans aged 65 and older using cardiovascular medications from January 2009 through June 2011.  The level of medication adherence was determined by the Proportion of Days Covered (PDC) over one year, meaning the percent of days that patients had medication on hand during that time-frame. Those with a PDC of 80 percent or higher were regarded as adherent, fol
'/>"/>

SOURCE Express Scripts
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2. Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure
3. FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure
4. Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR® for the Treatment of Heart Failure
5. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
6. Heart Hospital of Austin Physician First in Texas to Implant New Heart Failure Device
7. Drugs for Treating Congestive Heart Failure: Global Markets
8. Hypertronics Partners with UBM Canon, the Leading Global Medical Device Industry Source, to Co-Host Strategies for Avoiding Device Failure Seminar
9. Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients
10. American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11. Study Uncovers Key Success Factors and Common Failure Points for Launching New Metabolic Products in Todays Competitive Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... the Jefferies 2014 Boston Healthcare Summit next week in ... on August 6, 2014 and will not be webcast. ... BioPharma manages a portfolio of patents and royalty assets, ... patents and license agreements with various biotechnology and pharmaceutical ...
(Date:7/30/2014)... Die Apex Medical Corporation (Apex, ... Atemtherapie- und Druckzonenprodukte, gibt bekannt, dass sie ... anfechten werden. Dieses hat entschieden, dass die ... ResMed verletze. Apex weist darauf hin, dass ... Patente von ResMed Anfechtungen wegen Nichtigkeit eingeleitet ...
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- The global microbial identification ... methods, applications, end users, and geographies. Genotypic technology ... microbial identification market. This favorable growth is attributed ... and the time required for microbial identification along ... Furthermore, genotypic methods have high applications in clinical ...
Breaking Medicine Technology:PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6
... , TAMPA, Fla. , April 26 ... today that Zirgan™ (ganciclovir ophthalmic gel) 0.15% is now commercially ... Drug Administration in September 2009 , is a topical ... (dendritic ulcers).   , ...
... April 26 Aton Pharma, Inc., a ... acquired the U.S. marketing rights to LODOSYN® (carbidopa) tablets ... use with carbidopa-levodopa or with levodopa in the treatment ... administration of lower doses of levodopa with reduced nausea ...
Cached Medicine Technology:Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 2Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 4
(Date:7/30/2014)... Hayward, CA (PRWEB) July 30, 2014 ... and accessories at the lowest prices on the internet ... Lightning Cables in two lengths and two colors. These ... performance standards. , The high quality SF Cable ... 8-pin connector with digital signal delivering faster charging and ...
(Date:7/30/2014)... The family of a Vermont man ... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his death ... reports. According to the complaint, which was filed in ... July 25th, the decedent had been taking Xarelto for ... bleed that ultimately led to his death on August ...
(Date:7/30/2014)... Visitors to our region recognize how special it ... protection. Bob Kiesendahl, one of the owners of Woodloch ... Conservancy for donations collected through participation in the Green ... fast, as visitors welcome the opportunity to invest in ... The Kiesendahl family has owned Woodloch Resort for multiple ...
(Date:7/30/2014)... Some obese people have a genetic mutation that seems ... when they see food, researchers report. Gaining a ... pleasure and gratification at the sight of high-calorie foods ... overeating, the scientists suggested. More than one-third of ... by a combination of overeating, a lack of physical ...
(Date:7/30/2014)... KY (PRWEB) July 30, 2014 DRE ... pleased to announce the launch of its Medical ... online resource for medical professionals and equipment vendors. , ... shows and conventions in the United States and around ... the calendar, and that number is always growing. , ...
Breaking Medicine News(10 mins):Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Gene Mutation May Make Food More Tempting 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2
... metabolisms, which may help them generate the energy they need ... in the July Cell Metabolism , a Cell Press ... before detectable tumors form. By the same token, the studies ... metabolism shifts back before established tumors shrink. "This ...
... colorectal cancer risk, according to a new study in ... Gastroenterological Association (AGA) Institute. Folate is a water-soluble B ... that all forms and sources of folate were associated ... PhD, of the American Cancer Society and lead author ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... age 2 generally aren,t at risk for future behavioral or ... Kids who are speech-delayed, but don,t have any other developmental ... at age 2. But, the study found, those problems don,t ...
... , TUESDAY, July 5 (HealthDay News) -- People with ... increased risk of death, a new study indicates. ... January 2006 and September 2010 -- that looked at ... specified. Anorexics mistakenly believe they are fat and ...
... include Western lung cancer patients, first-line treatment with ... chemotherapy, according to research presented at the 14th ... by the International Association for the Study of ... kinase inhibitor (TKI) that targets the epidermal growth ...
... ingredients for long-term relationship satisfaction, according to an international ... committed relationships, but contrary to stereotypes, tenderness was more ... Also contrary to expectations of the researchers, men ... relationship, while women were more likely to report being ...
Cached Medicine News:Health News:Metabolic shift may offer early cancer clue 2Health News:High folate intake may reduce risk of colorectal cancer 2Health News:Tots Who Are 'Late Talkers' Typically Turn Out Fine: Study 2Health News:Tots Who Are 'Late Talkers' Typically Turn Out Fine: Study 3Health News:Eating Disorders Appear to Raise Risk of Death 2Health News:EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy 2Health News:Couples report gender differences in relationship, sexual satisfaction over time 2Health News:Couples report gender differences in relationship, sexual satisfaction over time 3
... The 9115-5.0 transducer ... transducer imaging at the ... (patented) HST technology, this ... quality when higher frequency ...
TOX/See is a 1-step, hand-held, point-of-care device for the qualitative detection of drug or drug metabolites in human urine....
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
Compact benchtop clinical chemistry system...
Medicine Products: